---
title: "Novavax Stock Rallies Tuesday: What's Happening?"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/296936385.md"
description: "Novavax (NVAX) shares rose 7% to $9.48 on Tuesday, driven by renewed investor interest in the vaccine sector following positive Phase 3 results from Moderna and Merck. The rally is also supported by Novavax's Q2 revenue of $56.7 million beating estimates, raised 2026 revenue guidance, cost reductions, and a strategic partnership with Sanofi for a combination COVID-19/flu vaccine trial."
datetime: "2026-08-25T15:31:25.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/296936385.md)
  - [en](https://longbridge.com/en/news/296936385.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/296936385.md)
generator: "portal-rs"
---

# Novavax Stock Rallies Tuesday: What's Happening?

Shares of **Novavax Inc** (NASDAQ:NVAX) are trading higher Tuesday morning as buying interest continues across late-stage vaccine developers. Here’s what investors need to know.

-   Novavax shares are climbing with conviction. Why are NVAX shares rallying?

## **Vaccine Pipeline Momentum And Sanofi Milestones Fuel Rebound**

Investor sentiment across the broader vaccine and mRNA space has strengthened following major clinical breakthroughs from sector peers, rekindling speculative interest in Novavax’s proprietary Matrix-M adjuvant technology and licensing pipeline. 

Sector momentum accelerated after Moderna and partner **Merck** announced positive Phase 3 trial results for their personalized mRNA cancer vaccine, demonstrating significant recurrence-free survival improvements in high-risk melanoma patients. 

The late-stage oncology breakthrough, combined with renewed institutional focus on combination respiratory vaccines, has revitalized buying interest across small- and mid-cap biotechnology developers in recent sessions.

## **Raised 2026 Revenue Guidance and Cost Structure Reductions Underpin Recovery**

Providing fundamental backing to Tuesday’s rally is the company’s second-quarter financial update announced on Aug. 6. Novavax posted second-quarter revenue of $56.7 million, topping Wall Street consensus estimates, and raised its full-year 2026 revenue guidance to between $235 million and $275 million. The raised outlook comes alongside ongoing cost-reduction measures and an advancing global co-development partnership with **Sanofi**.

Under the partnership, Sanofi is commercializing Nuvaxovid while working toward regulatory alignment for a Phase 3 COVID-19-Influenza Combination trial, which would trigger a $125 million milestone payment to Novavax upon initiation. 

With $724 million in cash and equivalents reported as of June 30, traders are bidding up the stock as execution on commercial milestones and reduced R&D burn improve its medium-term financial outlook.

## NVAX Stock Climbs Tuesday Morning

**NVAX Price Action:** Novavax shares were up 7% at $9.48 at the time of publication on Tuesday, according to Benzinga Pro data.

 **Read Also: Bausch + Lomb Advances Two Eye Therapies With Blockbuster Sales Potential** 

*Image: Shutterstock*

### Related Stocks

- [NVAX.US](https://longbridge.com/en/quote/NVAX.US.md)
- [MRK.US](https://longbridge.com/en/quote/MRK.US.md)
- [MRNA.US](https://longbridge.com/en/quote/MRNA.US.md)
- [SNY.US](https://longbridge.com/en/quote/SNY.US.md)
- [MRNX.US](https://longbridge.com/en/quote/MRNX.US.md)
- [MRNY.US](https://longbridge.com/en/quote/MRNY.US.md)
- [BLCO.US](https://longbridge.com/en/quote/BLCO.US.md)
- [SNYNF.US](https://longbridge.com/en/quote/SNYNF.US.md)

## Related News & Research

- [How Cathie Wood's fund gave us a back door to Moderna's breakthrough](https://longbridge.com/en/news/298769510.md)
- [Amundi Reduces Stock Holdings in Moderna, Inc. $MRNA](https://longbridge.com/en/news/298693237.md)
- [Moderna (NASDAQ:MRNA) Insider Sells $485,766.45 in Stock](https://longbridge.com/en/news/297959605.md)
- [Merck (MRK), Why Is Its Latest Update Raising Bigger Questions?](https://longbridge.com/en/news/298090109.md)
- [NewEdge Advisors LLC Purchases 41,950 Shares of Merck & Co., Inc. $MRK](https://longbridge.com/en/news/298434406.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**